Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

J. Schwarz, P. Ovesná, O. Černá, J. Kissová, J. Maaloufová Soukupová, Y. Brychtová, M. Doubek, L. Červinek, E. Cmunt, P. Dulíček, V. Campr, L. Křen, M. Penka, . ,

. 2016 ; 96 (1) : 98-106. [pub] 20150421

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17001175

Controversies still exist regarding definition of the thrombotic risks in Ph- (BCR/ABL1-) myeloproliferative disorders with thrombocythemia (MPD-T). Platelet counts at diagnosis are currently not taken as a risk factor of thrombosis. In our cohort of 1179 patients with MPD-T, prospectively registered for anagrelide treatment, we found that the median platelet count prior to the thrombotic event was significantly higher than at time points without any ensuing thrombosis (453 vs. 400 × 10(9)/L, P < 0.001), albeit higher platelet counts at diagnosis tended to be connected with fewer thrombotic events (in contrast to WBC counts at diagnosis). The JAK2(V617F) mutation predicted both arterial and venous events, while age >65 yr, hypertension, diabetes mellitus, smoking, elevated triglyceride and homocysteine levels predicted arterial events only. For venous events, the specific thrombophilic risk factors (factor V 'Leiden' and others), antiphospholipid antibodies, and elevated factor VIII levels played a major role. During anagrelide treatment (± aspirin), we documented a decrease in both venous (6.7-fold) and arterial events (1.8-fold), while bleeding (mostly minor events) increased twofold compared to history. Our results suggest that keeping platelet counts at low levels may be a meaningful therapeutic measure to prevent thrombosis, although their counts at diagnosis lack any prognostic value.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17001175
003      
CZ-PrNML
005      
20170116095038.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12554 $2 doi
024    7_
$a 10.1111/ejh.12554 $2 doi
035    __
$a (PubMed)25807961
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schwarz, Jiří $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, 1st Medical Faculty, Charles University, Prague, Czech Republic.
245    10
$a Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide / $c J. Schwarz, P. Ovesná, O. Černá, J. Kissová, J. Maaloufová Soukupová, Y. Brychtová, M. Doubek, L. Červinek, E. Cmunt, P. Dulíček, V. Campr, L. Křen, M. Penka, . ,
520    9_
$a Controversies still exist regarding definition of the thrombotic risks in Ph- (BCR/ABL1-) myeloproliferative disorders with thrombocythemia (MPD-T). Platelet counts at diagnosis are currently not taken as a risk factor of thrombosis. In our cohort of 1179 patients with MPD-T, prospectively registered for anagrelide treatment, we found that the median platelet count prior to the thrombotic event was significantly higher than at time points without any ensuing thrombosis (453 vs. 400 × 10(9)/L, P < 0.001), albeit higher platelet counts at diagnosis tended to be connected with fewer thrombotic events (in contrast to WBC counts at diagnosis). The JAK2(V617F) mutation predicted both arterial and venous events, while age >65 yr, hypertension, diabetes mellitus, smoking, elevated triglyceride and homocysteine levels predicted arterial events only. For venous events, the specific thrombophilic risk factors (factor V 'Leiden' and others), antiphospholipid antibodies, and elevated factor VIII levels played a major role. During anagrelide treatment (± aspirin), we documented a decrease in both venous (6.7-fold) and arterial events (1.8-fold), while bleeding (mostly minor events) increased twofold compared to history. Our results suggest that keeping platelet counts at low levels may be a meaningful therapeutic measure to prevent thrombosis, although their counts at diagnosis lack any prognostic value.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a substituce aminokyselin $7 D019943
650    _2
$a Aspirin $x aplikace a dávkování $7 D001241
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzní proteiny $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a missense mutace $7 D020125
650    12
$a filadelfský chromozom $7 D010677
650    _2
$a počet trombocytů $7 D010976
650    _2
$a prospektivní studie $7 D011446
650    _2
$a chinazoliny $x aplikace a dávkování $7 D011799
650    12
$a registrace $7 D012042
650    _2
$a rizikové faktory $7 D012307
650    12
$a trombocytóza $x krev $x komplikace $x farmakoterapie $x genetika $7 D013922
650    12
$a trombóza $x krev $x farmakoterapie $x etiologie $x genetika $7 D013927
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ovesná, Petra $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
700    1_
$a Černá, Olga $u Internal Hematology Clinic, Faculty Hospital Královské Vinohrady, Prague, Czech Republic.
700    1_
$a Kissová, Jarmila $u Department of Clinical Hematology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Maaloufová Soukupová, Jacqueline $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine - Hematology and Oncology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Červinek, Libor $u Department of Internal Medicine - Hematology and Oncology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Cmunt, Eduard $u Department of Clinical Hematology of the 1st Department of Internal Medicine, 1st Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Dulíček, Petr $u 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic.
700    1_
$a Campr, Vít $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Pathological Anatomy, 2nd Medical Faculty, Faculty Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a Křen, Leoš $u Department of Pathology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Penka, Miroslav $u Department of Clinical Hematology, Faculty Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a ,
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 96, č. 1 (2016), s. 98-106
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25807961 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170116095143 $b ABA008
999    __
$a ok $b bmc $g 1180315 $s 961742
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 96 $c 1 $d 98-106 $e 20150421 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace